Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
about
Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation.Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.Anticoagulating obese patients in the modern era.Adherence to guidelines for the prescribing of double and triple combinations of antithrombotic agents.Newer antithrombotic drugs
P2860
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
@en
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
@nl
type
label
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
@en
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
@nl
prefLabel
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
@en
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding.
@nl
P2860
P1476
Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding
@en
P2093
F A Spencer
P2860
P304
P356
10.1111/J.1538-7836.2010.03737.X
P50
P577
2010-01-06T00:00:00Z